Synthesis and in vivo evaluation of [18F]-4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide as a PET imaging probe for COX-2 expression
摘要:
Synthesis of [F-18]4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide ([F-18]celecoxib), a selective COX-2 inhibitor, is achieved via a bromide to [F-18]F- exchange reaction. Synthesis of the precursor for radiolabeling was achieved from 4'-methylacetophenone in four steps with 22% overall yield. Under non-radioactive conditions, fluorination was achieved using TBAF in DMSO at 135 degrees C in 80% yield. Synthesis of [F-18]celecoxib was achieved using [F-18]TBAF in DMSO at 135 degrees C in 10 +/- 2% yield (EOS) with > 99% chemical and radiochemical purities. The specific activity was 120 +/- 40 mCi/mu mol (EOB). [F-18]celecoxib was found to be stable in ethanol, however, de[F-18]fluorination (6.5%) was observed after 4 h in 10% ethanol-saline solution. Rodent PET studies show bone labeling indicating in vivo de[F-18]fluorination of [F-18]celecoxib. PET studies in baboon indicated a lower rate of de[F-18]fluorination than rat and retention of radioactivity in brain regions consistent with the known distribution of COX-2. A radiolabeling method that can generate consistent high specific activity is needed for routine human use. (c) 2006 Elsevier Ltd. All rights reserved.
Synthesis and in vivo evaluation of [18F]-4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide as a PET imaging probe for COX-2 expression
作者:Jaya Prabhakaran、Mark D. Underwood、Ramin V. Parsey、Victoria Arango、Vattoly J. Majo、Norman R. Simpson、Ronald Van Heertum、J. John Mann、J.S. Dileep Kumar
DOI:10.1016/j.bmc.2006.11.033
日期:2007.2
Synthesis of [F-18]4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide ([F-18]celecoxib), a selective COX-2 inhibitor, is achieved via a bromide to [F-18]F- exchange reaction. Synthesis of the precursor for radiolabeling was achieved from 4'-methylacetophenone in four steps with 22% overall yield. Under non-radioactive conditions, fluorination was achieved using TBAF in DMSO at 135 degrees C in 80% yield. Synthesis of [F-18]celecoxib was achieved using [F-18]TBAF in DMSO at 135 degrees C in 10 +/- 2% yield (EOS) with > 99% chemical and radiochemical purities. The specific activity was 120 +/- 40 mCi/mu mol (EOB). [F-18]celecoxib was found to be stable in ethanol, however, de[F-18]fluorination (6.5%) was observed after 4 h in 10% ethanol-saline solution. Rodent PET studies show bone labeling indicating in vivo de[F-18]fluorination of [F-18]celecoxib. PET studies in baboon indicated a lower rate of de[F-18]fluorination than rat and retention of radioactivity in brain regions consistent with the known distribution of COX-2. A radiolabeling method that can generate consistent high specific activity is needed for routine human use. (c) 2006 Elsevier Ltd. All rights reserved.
Synthesis of bromodifluoromethyl substituted pyrazoles and isoxazoles
Bromodifluoromethyl substituted β-diketone 3a–3d, prepared from corresponding ketones and ethyl bromodifluoroactate in the presence of sodium methoxide, reacted with aryl hydrazine derivatives affording bromodifluoromethyl substituted pyrazoles in high regioselectivity. The reaction of 3a–3d with hydroxylamine hydrochloride gave dihydroisoxazoles, which afforded bromodifluoromethyl substitutedisoxazoles through